Results 71 to 80 of about 202,276 (321)

Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead [PDF]

, 2015
Non-Hodgkin lymphoma is the fourth most common malignancy in children, has an even higher incidence in adolescents, and is primarily represented by only a few histologic subtypes. Dramatic progress has been achieved, with survival rates exceeding 80%, in
Auperin, Anne, Brugi\ue8res, Laurence, Burkhardt, Birgit, Cairo, Mitchell S, Damm Welk, Christine, Gross, Thomas G, Horibe, Keizo, Klapper, Wolfram, Lamant, Laurence, Le Deley, Marie C\ue9cile, Macintyre, Elizabeth, Minard Colin, V\ue9ronique, Mussolin, Lara, Patte, Catherine, Perkins, Sherrie L, Pillon, Marta, Poirel, H\ue9l\ue8ne A, Raphael, Martine, Reiter, Alfred, Rosolen, Angelo, Sandlund, John T, Williams, Denise, Woessmann, Wilhelm, Zimmerman, Martin   +23 more
core   +1 more source

WDR5‐H3K4me3 Epigenetic Axis Promotes TRMT6‐Dependent tRNA M1A Modification to Facilitate Triple‐Negative Breast Cancer Progression by Suppressing Ferroptosis

Advanced Science, EarlyView.
Upregulated TRMT6 forms aberrant hypermethylation of a specific tRNA pool and serves as a predictor of poor prognosis in TNBC. This m1A modification in tRNAs enhances translation of FTH1 and FTL, reducing the pool of bioavailable Fe2⁺. Reduced Fe2+ availability impairs RSL3‐induced lipid peroxidation and tumor progression.
Yuqing Lei, Xue Wang, Jiahe Liu, Zixu Niu, Jiaqi Hua, Qian Guo, Dan Du, Yuanchang Zhu, Fucheng He, Mingxia Zhou, Hongle Li, Jing He, Jun Li   +12 more
wiley   +1 more source

Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. [PDF]

, 2017
Purpose: B-cell lymphomas must acquire resistance to apoptosis during their development. We recently discovered BCLW, an antiapoptotic BCL2 family member thought only to contribute to spermatogenesis, was overexpressed in diffuse large B-cell lymphoma ...
Adams, Clare M., Eischen, Christine M., Gong, MD, Jerald Z., Mitra, Ramkrishna   +3 more
core   +1 more source

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience [PDF]

, 2017
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B ...
A Abulayha, A Chanan-Khan, A Davies, A Prica, AR Rezvani, B Bonavida, B Coiffier, B Coiffier, B Coiffier, B Eichhorst, B Eichhorst, BS Kahl, C Dartigeas, C Gisselbrecht, C Müller, C Taverna, CS Tam, D Daydé, D Müller, D Rossi, David G. Maloney, DG Maloney, DG Maloney, DG Maloney, DW Scott, E Bachy, E Deconinck, E Hoster, E Kimby, E Vellenga, E Zucca, EA Chong, EJ Soini, FB Hagemeister, FT Awan, G Köhler, G Lenz, G Martinelli, G Poeta Del, G Poeta Del, G Salles, G Salles, GA Salles, Gilles Salles, GJ Weiner, GJ Weiner, H Blasco, H Hochster, H Schulz, H Tilly, HC Kluin-Nelemans, HM Blommestein, HR Junlén, International CLL-IPI Working Group, J Banchereau, J Hiraga, J Hornberger, J Hornberger, J Li, JA Ray, JA Woyach, JC Byrd, JC Byrd, JM Foran, JM Vose, JO Armitage, Joerg Maurer, JP Leonard, K Fischer, K Fischer, K Fischer, K Tobinai, K Tobinai, KA Foon, KA Foon, KM Ardeshna, KM Johnston, L Li, L Tran, L Vidal, LA Torre, LD Piro, LM Nadler, M Adena, M Dreyling, M Dreyling, M Federico, M Feuring-Buske, M Hallek, M Hallek, M Herold, M Jermann, M Pfreundschuh, M Pfreundschuh, M Pfreundschuh, M Tout, MA Dimopoulos, MA Lopez-Olivo, Martin Barrett, MB Regazzi, MD Danese, ME Reff, ME Williams, MH Oers van, MH Oers van, Michael Wenger, MJ Keating, MJ Rummel, MS Czuczman, MS Czuczman, Nancy Valente, NL Berinstein, O Mandrik, OW Press, P Abrisqueta, P Boffetta, P Boross, P Colombat, P Feugier, P Hillmen, P McLaughlin, P Thompson, PV Beum, Q Chen, Q Chen, R Forstpointner, R Forstpointner, R Foà, R Griffiths, R Marcus, R Marcus, RA Miller, RI Griffiths, RI Griffiths, RL Elstrom, Robin Foà, S Assouline, S Cang, S Khor, S Maury, SG Fisher, SM Jaglowski, SM O’Brien, Susan O’Brien, T Igarashi, T Kewalramani, T Robak, TA Davis, TA Davis, TJ Kipps, TM Habermann, U Jaeger, U Jäger, UJ Mey, V Goede, V Ivanov, V Minard-Colin, V Ribrag, W Hiddemann, W Wierda, XC Badoux, Y Oki   +161 more
core   +2 more sources

Functional, Pharmacogenomic, and Immune Landscapes of Long Non‐Coding RNAs in Cancer

Advanced Science, EarlyView.
A systematic analysis of 33 cancer types reveals widespread associations between lncRNAs and cancer pathways, drug responses, immune features, and immunotherapy outcomes. The study identifies key lncRNAs linked to therapeutic response and adverse events and introduces PILNC, an interactive web portal for exploring the functional, pharmacogenomic, and ...
Runhao Wang, Mei Luo, Yuan Liu, Jingwen Yang, Yamei Chen, Chengxuan Chen, Lifei Ma, Stephanie Ding, James Wengler, Yong Zang, Bora Lim, Wenbo Li, Liuqing Yang, Chunru Lin, Lixia Diao, Leng Han   +15 more
wiley   +1 more source

Postmortem Detection of “Clinically Undiagnosed” Diffuse Large B-Cell Lymphoma: Gross and Microscopic Findings

Diagnostics
Diffuse large B-cell lymphoma is considered the most found non-Hodgkin lymphoma in adults. Diffuse large B-cell lymphoma, which also occurs in sporadic forms, is associated with some pathological conditions, including human immunodeficiency virus ...
Vincenzo Cianci, Daniela Sapienza, Giovanni Bartoloni, Alessio Cianci, Annalisa Cracò, Fausto Omero, Patrizia Gualniera, Alessio Asmundo, Cristina Mondello   +8 more
doaj   +1 more source

Central nervous system intravascular lymphoma in a Malaysian. [PDF]

, 2011
Intravascular lymphoma (IVL) is a rare subtype of extranodal diffuse large cell lymphoma, characterized by intravascular proliferation of B or T lymphocytes within small blood vessels; which may lead to occlusive symptoms, its neurological involvement ...
Al-Edrus, Sharifah Aishah, Gan, Gin Gin, Ganesan, Dharmendra, Looi, Lai Meng, Mohamed Mukari, Shahizon Azura, Noordin, Mazin, Rahmat, Kartini, Ramli, Norlisah, Tan, Chong Tin   +8 more
core  

Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply [PDF]

, 2017
n
Chiappella, Annalisa, Evangelista, Andrea, Martelli, Maurizio, Vitolo, Umberto   +3 more
core   +1 more source

IL4I1⁺ Macrophages and TDO2⁺ Myofibroblasts Drive AhR‐Mediated Immunosuppression and Ferroptosis Resistance in Solid Predominant Lung Adenocarcinoma

Advanced Science, EarlyView.
Solid predominant lung adenocarcinoma exhibits an immune‐excluded, ferroptosis‐resistant niche enriched with IL4I1⁺ TAMs and TDO2⁺ myCAFs. Spatial and multi‐omics analyses reveal AhR‐driven crosstalk that promotes T cell exhaustion and therapy resistance. Blocking AhR with CH‐223191 restores ferroptosis sensitivity, and its combination with ferroptosis
Zhaoxuan Wang, Weijiao Xu, Lei Zhao, Lin Zhong, Wendan Yu, Shengmin Wang, Lu Sun, Tao Guo, Fengzhou Li, Zhuoshi Li, Lei Fang, Shiqing Wang, Guohui Zhang, Guoqing Xue, Wei Guo, Shilei Zhao, Chundong Gu   +16 more
wiley   +1 more source

Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma with mutation: A case report

SAGE Open Medical Case Reports
Despite advancements in the treatment of diffuse large B-cell lymphoma, including CAR T-cell therapy, TP53 mutations remain a significant negative prognostic factor in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ziyi Cai, Dongmei Zou, Qiang Ma, Wanling Sun, Yixian Guo   +4 more
doaj   +1 more source